GLP-1 medicines are FDA-approved to treat type 2 diabetes and obesity
Ongoing clinical trials in peripheral vascular disease, neuropsychiatric and substance use disorders, metabolic liver disease, arthritis, hypertension and neurodegenerative disorders may broaden indications for GLP-1-based therapeutics
This is where MeAgain's GLP-1 app fits in: it centralizes dose timelines, symptom and hydration logs, and lab entries, enabling clinicians to interpret test changes more quickly and precisely
Its wellness, delivered with intention and precision
What Are Direct-Acting Oral Anticoagulants
Medical authorities emphasize that investigational drugs should remain within clinical trials and that consumers should avoid black-market products because of unknown composition, dosing, sterility, and safety